Powerful Computer Vision to aid Radiologists

Our flagship solution, VisiRad™, uses sophisticated computer vision technology to identify lung nodules in chest x-rays. VisiRad, the cornerstone to our mission of improving lung cancer outcomes, is modeled after the expert accuracy and acumen of world-class radiologists practicing at the top of their license.

Identifying overlooked lung nodules is an opportunity to stage-shift lung cancer and treat patients sooner

Early detection is the key to improving outcomes for cancer patients. Currently, 49% of lung cancer diagnoses occur at Stage IV, where the cancer has metastasized to other organs and the prognosis is often grim—the 5-year survival rate for stage IV lung cancer is only 10%.

Many reasons exist for the prevalence of late-stage diagnoses. Importantly, lung cancer is generally asymptomatic until these late stages and is often only detected incidentally, when a chest x-ray is performed for another reason. Lung nodules, indicating early lung cancer, can be detected in these x-rays however are often overlooked because the visual appearance is extremely subtle, can be confounded with normal anatomical features such as a blood vessel, and are a rare finding that decreases vigilance. Combine that with an intense workloads for radiologists (over 240million x-rays are performed per year in the US) ,and you see that 20-50% of lung nodules present in chest X-rays are overlooked during routine care. 

Diagnosing earlier

Simply diagnosing lung nodules early on, at stage I, shifts the 5-year survival rate form a mere 10% at Stage IV to 70-90%—that’s up to an 80% better survival rate. If providers identified every lung nodule present in chest X-rays conduct in routine care, over 100,000 people in the US could have their cancer diagnosis stage shifted and can look forward to better outcomes. With the reduced costs associated with treating lung cancer at earlier stages, the positive impact on both patient outcomes and our health care system are obvious. For healthcare providers, the financial impact of additional diagnoses is no less relevant—each additional diagnosis represents another cancer patient to treat, increasing top line revenue and reducing exposure to medical malpractice.

VisiRad™ puts findings

in plain view

Our Model Is Different

 What makes VisiRad different? Other solutions may base their models on x-ray findings alone, where the error rate can be 20-50%. Even as the solution gains more information and “learns” about diagnostic similarities between cases, it is still based on that intrinsic error rate. It may not be able to exceed that rate ats it continues to base its model on flawed data.

VisiRad takes a different approach. Our model is based on a growing contributory database consortium using longitudinal outcomes from CT Scans to pathology reports where the error rate is less than 5%. Combined with our computer vision technology and advanced machine learning, this more accurate data will lead to a new standard of care based on superior diagnostic accuracy.

VisiRad is available for research purposes only.  It is not for sale for clinical use.  

Sign up for a complimentary evaluation with VisiRad*

  • This field is for validation purposes and should be left unchanged.

*For Research Purposes. Click here for more information on participation, privacy and security.